Literature DB >> 16227362

Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites.

M Bolognesi1, D Sacerdoti, M Di Pascoli, P Angeli, S Quarta, A Sticca, P Pontisso, C Merkel, A Gatta.   

Abstract

BACKGROUND AND AIMS: Haeme oxygenase could play a role in the pathogenesis of arterial vasodilation in cirrhosis. The aim of this study was to verify the role of haeme oxygenase in the hyporesponsiveness to phenylephrine of small mesenteric arteries in rats with CCl(4) induced cirrhosis, with and without ascites.
METHODS: Pressurised small resistance mesenteric arteries were challenged with increasing doses of phenylephrine. Dose-response curves were evaluated under basal conditions, after inhibition of haeme oxygenase with chromium-mesoporphyrin, after inhibition of nitric oxide synthase (NOS) with N(G)-nitro-L-arginine-methyl-ester (L-NAME), and then after inhibition of both NOS and haeme oxygenase. Haeme oxygenase protein expression was also analysed.
RESULTS: Twenty six control rats and 35 rats with cirrhosis (17 with and 18 without ascites) were studied. Response to phenylephrine was lower in non-ascitic and ascitic cirrhosis than in controls. Chromium-mesoporphyrin increased the response to phenylephrine only in ascitic cirrhosis (p<0.001). L-NAME increased the response to phenylephrine in controls (p<0.001) and in ascitic and non-ascitic cirrhosis (p = 0.002, p<0.001, respectively) but the final response in non-ascitic cirrhosis was similar to that of control rats while it remained impaired in ascitic cirrhosis. Addition of chromium-mesoporphyrin to L-NAME improved the response to phenylephrine in ascitic cirrhosis (p<0.01), with final values not different from those of the other two groups. Protein expression of the inducible isoform of haeme oxygenase was increased in the mesenteric vessels of cirrhotic rats.
CONCLUSION: Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of experimental cirrhosis with ascites. NOS plays a major role only in the first stage of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227362      PMCID: PMC1774733          DOI: 10.1136/gut.2004.063735

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  32 in total

1.  Gene therapy and heme oxygenase coming of age.

Authors:  Richard J Roman
Journal:  Hypertension       Date:  2004-06       Impact factor: 10.190

Review 2.  Structure and function of small arteries.

Authors:  M J Mulvany; C Aalkjaer
Journal:  Physiol Rev       Date:  1990-10       Impact factor: 37.312

3.  Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity.

Authors:  M Fernandez; R W Lambrecht; H L Bonkovsky
Journal:  J Hepatol       Date:  2001-06       Impact factor: 25.083

4.  In vitro hyporeactivity to methoxamine in portal hypertensive rats: reversal by nitric oxide blockade.

Authors:  C C Sieber; R J Groszmann
Journal:  Am J Physiol       Date:  1992-06

5.  Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis.

Authors:  Dara De las Heras; Javier Fernández; Pere Ginès; Andres Cárdenas; Rolando Ortega; Miguel Navasa; Joan Albert Barberá; Blas Calahorra; Mónica Guevara; Ramón Bataller; Wladimiro Jiménez; Vicente Arroyo; Juan Rodés
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

6.  Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats.

Authors:  Yung-Chang Chen; Pere Ginès; Jianhui Yang; Sandra N Summer; Sandor Falk; Nash S Russell; Robert W Schrier
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

7.  Vascular CO counterbalances the sensitizing influence of 20-HETE on agonist-induced vasoconstriction.

Authors:  Jun-Ichi Kaide; Fan Zhang; Yuan Wei; WenHui Wang; Venkat Raj Gopal; John R Falck; Michal Laniado-Schwartzman; Alberto Nasjletti
Journal:  Hypertension       Date:  2004-06-28       Impact factor: 10.190

8.  Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats.

Authors:  C C Sieber; J C Lopez-Talavera; R J Groszmann
Journal:  Gastroenterology       Date:  1993-06       Impact factor: 22.682

9.  The effect of nitric oxide synthase inhibition on portal pressure and azygos blood flow in patients with cirrhosis.

Authors:  E H Forrest; A L Jones; J F Dillon; J Walker; P C Hayes
Journal:  J Hepatol       Date:  1995-09       Impact factor: 25.083

10.  Hyporeactivity of mesenteric resistance arteries in portal hypertensive rats.

Authors:  P Sogni; S Sabry; R Moreau; A Gadano; D Lebrec; A T Dinh-Xuan
Journal:  J Hepatol       Date:  1996-04       Impact factor: 25.083

View more
  8 in total

1.  Local regulator adrenomedullin contributes to the circulatory disturbance in cirrhotic rats.

Authors:  Shinya Sakurai; Hideyuki Kojima; Masahito Uemura; Hiroyasu Satoh; Hiroshi Fukui
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

2.  Synergistic antioxidant and anti-inflammatory action of N-acetylcysteine in portal hypertensive gastropathy in rats.

Authors:  Francielli Licks; Renata Minuzzo Hartmann; Elizângela Schemitt; Josieli Raskopf Colares; Camila Marques; Henrique Fillmann; Norma Possa Marroni
Journal:  Hepatol Forum       Date:  2022-04-26

Review 3.  Natural heme oxygenase-1 inducers in hepatobiliary function.

Authors:  Giovanni Li Volti; David Sacerdoti; Claudia Di Giacomo; Maria-Luisa Barcellona; Antonio Scacco; Paolo Murabito; Antonio Biondi; Francesco Basile; Diego Gazzolo; Raul Abella; Alessandro Frigiola; Fabio Galvano
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

Review 4.  Peculiar characteristics of portal-hepatic hemodynamics of alcoholic cirrhosis.

Authors:  Massimo Bolognesi; Alberto Verardo; Marco Di Pascoli
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

5.  HO-1 induction improves the type-1 cardiorenal syndrome in mice with impaired angiotensin II-induced lymphocyte activation.

Authors:  Sumit R Monu; Paola Pesce; Komal Sodhi; Massimo Boldrin; Nitin Puri; Larisa Fedorova; David Sacerdoti; Stephen J Peterson; Nader G Abraham; Attallah Kappas
Journal:  Hypertension       Date:  2013-06-10       Impact factor: 10.190

Review 6.  Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis.

Authors:  Massimo Bolognesi; Marco Di Pascoli; Alberto Verardo; Angelo Gatta
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 7.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

Review 8.  Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.

Authors:  Lakmie S Gunarathne; Harinda Rajapaksha; Nicholas Shackel; Peter W Angus; Chandana B Herath
Journal:  World J Gastroenterol       Date:  2020-10-28       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.